Recent Developments in the Drug Treatment of Parkinson's Disease - PubMed
3 hours ago
- #Parkinson's Disease
- #Drug Treatment
- #Levodopa
- Levodopa remains the gold-standard for symptomatic treatment of Parkinson's motor symptoms, but its chronic use often leads to response oscillations and dyskinesias.
- New delivery methods for levodopa, such as extended-release oral formulations, inhaled powder, and subcutaneous or intrajejunal infusions, aim to provide more continuous drug delivery.
- Novel dopamine agonists like tavapadon, a D1/D5 receptor partial agonist, have shown efficacy as monotherapy in early PD and as an adjunct to levodopa for motor fluctuations.
- Non-dopaminergic treatments, such as amantadine for dyskinesia and botulinum toxin for sialorrhea, are gaining evidence, but few PD-specific approvals for non-motor symptoms have emerged recently.
- Disease-modifying therapies are still lacking, with ongoing research focusing on GLP1 agonists, GBA pathway targeting, LRRK2 inhibition, and α-synuclein-based treatments, but without conclusive efficacy evidence yet.